(Q37523962)

20 August 2017

1 reference

title

Strategies to improve drug delivery in bladder cancer therapy (English)

1 reference

20 August 2017

1 reference

M Wirth

1

1 reference

20 August 2017

V E Plattner

series ordinal

2

1 reference

20 August 2017

F Gabor

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

Expert Opinion on Drug Delivery

20 August 2017

1 reference

20 August 2017

6

1 reference

20 August 2017

7

1 reference

20 August 2017

727-744

1 reference

Epidemiology of urinary bladder cancer: from tumor development to patient's death

20 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Epidemiology and genetic susceptibility to bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Bladder cancer: epidemiology, staging and grading, and diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Novel therapeutics in the treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Sustained intravesical drug delivery using thermosensitive hydrogel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Biodegradable block copolymers as injectable drug-delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Bioadhesive drug delivery system using glyceryl monooleate for the intravesical administration of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Anti-tumor effects of liposome-encapsulated titanium dioxide in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Hypericin in cancer treatment: more light on the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Photophysical properties of Hypericum perforatum L. extracts--novel photosensitizers for PDT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

The epidermal growth factor receptor and the prognosis of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Mechanism of action of erbB tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Recent advances of novel targeted therapy in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

21 January 2018

Focus on bladder cancer

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Intracellular protein degradation from a vague idea through the lysosome and the ubiquitin-proteasome system and on to human diseases and drug targeting: Nobel Lecture, December 8, 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Inhibition of DNA methylation and reactivation of silenced genes by zebularine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Variable Bcl-2 phenotype in benign and malignant lesions of urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Caspase involved synergistic cytotoxicity of bcl-2 antisense oligonucleotides and adriamycin on transitional cell cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Clusterin/apolipoprotein J in human aging and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Angiogenic factors and bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

VEGF receptor expression and signaling in human bladder tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Differential endostatin binding to bladder, prostate and kidney tumour vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Molecular changes in carbohydrate antigens associated with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Lectin-mediated drug targeting: preparation, binding characteristics, and antiproliferative activity of wheat germ agglutinin conjugated doxorubicin on Caco-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Targeted drug delivery: binding and uptake of plant lectins using human 5637 bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Treatment options for high-risk T1 bladder cancer: status quo and future perspectives of radiochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Matrix metalloproteinases and tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Inhibitory effects of the aqueous extract of Magnolia officinalis on the responses of human urinary bladder cancer 5637 cells in vitro and mouse urinary bladder tumors induced by N-Butyl-N-(4-hydroxybutyl) nitrosamine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Development and application of Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Targeting Hsp90: small-molecule inhibitors and their clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Cell-penetrating peptides as delivery vehicles for biology and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

In vivo protein transduction: delivery of a biologically active protein into the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

Preliminary European Results of Local Microwave Hyperthermia and Chemotherapy Treatment in Intermediate or High Risk Superficial Transitional Cell Carcinoma of the Bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903022758

10.1517/17425240903022758

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference